Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome (Nasdaq: IMNM) has partnered with Abzena to develop IMM-BCP-01, an investigational antibody cocktail targeting COVID-19. This collaboration is aimed at producing the cocktail for clinical testing. In July 2020, Immunome received $13.3 million from the U.S. Department of Defense to support this initiative. Both companies emphasize the potential benefits of this therapy in combating the pandemic. Immunome focuses on developing first-in-class therapeutic antibodies utilizing its proprietary human memory B cell platform.
Immunome, Inc. (Nasdaq: IMNM) announced findings from its preclinical COVID-19 research, highlighting the role of non-Spike antibodies in virus clearance. Key results show over 50% of antibodies from super-responders target non-Spike antigens, including nucleocapsid proteins and ORF8/ORF10. The study suggests potential for developing an optimized antibody cocktail to combat the mutational drift of the Spike protein. This research is part of a $13.3 million agreement with the Department of Defense, supporting Immunome’s COVID therapeutic programs.
Immunome, Inc. (Nasdaq: IMNM) recently appointed Richard Baron to its Board of Directors and Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer. These appointments are anticipated to enhance Immunome's capabilities in antibody discovery and clinical program advancement. Additionally, CEO Purnanand Sarma received TiE Boston's 2020 Lifetime Achievement Award for his contributions to science and entrepreneurship. The press release emphasizes the company's commitment to innovating antibody therapeutics targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced Q3 2020 financial results, highlighting a significant milestone with the completion of its IPO, yielding $44.9 million in gross proceeds. The company aims to advance clinical programs for oncology and COVID-19 treatments, including filing IND applications in 2021. Key financial metrics reveal cash and cash equivalents at $6.7 million and a net loss of $8.4 million, equating to $7.52 per share. The R&D expenses decreased from $2.2 million in Q3 2019 to $1.6 million in Q3 2020, while G&A expenses increased considerably from $0.5 million in the same period.
Immunome, Inc. (Nasdaq: IMNM) has announced the full exercise of the underwriters' option for 487,500 additional shares at $12.00 each, raising approximately $5.9 million in gross proceeds. This follows their initial public offering, totaling 3,737,500 shares sold and gross proceeds of about $44.9 million before expenses. The offering, effective as of October 1, 2020, enhances Immunome's funding to continue its focus on oncology and infectious diseases, leveraging its innovative memory B cell platform for therapeutic development.
Immunome, Inc. (Nasdaq: IMNM) has announced the pricing of its initial public offering, now upsized to 3,250,000 shares at $12.00 per share, totaling approximately $39.0 million in gross proceeds. This offering includes a 30-day option for underwriters to purchase an additional 487,500 shares. Trading is set to commence on the Nasdaq Capital Market on October 2, 2020, with the offering expected to close on October 6, 2020. Ladenburg Thalmann & Co. and Chardan are the book-running managers.